Article

Avedro, EyeGate Pharma to enter agreement

EyeGate Pharma’s broad iontophoresis patent portfolio for corneal collagen cross-linking will be held as exclusive license by Avedro Inc. Delivery approach provides potential additional benefits to current formulation.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Survey highlights gender and racial disparities in ophthalmology
December 10th 2024

Survey highlights gender and racial disparities in ophthalmology

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Beacon Therapeutics announces positive 3-month data from Phase 2 DAWN trial of AGTC-501 in patients with X-linked retinitis pigmentosa
December 10th 2024

Beacon Therapeutics announces positive 3-month data from Phase 2 DAWN trial of AGTC-501 in patients with X-linked retinitis pigmentosa

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

New study highlights retinopathy risk from hair dye use
December 9th 2024

New study highlights retinopathy risk from hair dye use

Generative AI: It’s only just begun
December 9th 2024

Generative AI: It’s only just begun

© 2024 MJH Life Sciences

All rights reserved.